Cost-effectiveness of continuous versus intermittent chemotherapy for patients with HER2-negative advanced breast cancer.
Anouk K M ClaessensJan J V BusschbachBram L T RamaekersFrans L G ErdkampJeanette M BoumaA Elise van Leeuwen-StokVivianne C G Tjan-HeijnenMonique E M M Bosnull nullPublished in: Acta oncologica (Stockholm, Sweden) (2022)